HEIDELBERG PHARMA AG O.N./ DE000A11QVV0 /
10/10/2024 9:49:36 PM | Chg. +0.0900 | Volume | Bid9:49:39 PM | Ask9:58:00 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
2.4900EUR | +3.75% | 0 Turnover: 0.0000 |
-Bid Size: - | -Ask Size: - | 87.15 mill.EUR | 0.00% | - |
GlobeNewswire
11/16/2017
Antibody Drug Conjugates Market, 2030 - Market is Anticipated to Grow at a CAGR to 19.4%
GlobeNewswire
11/12/2007
HEIDELBERG PHARMA AG starts second clinical phase II study with FOSALVUDINE
GlobeNewswire
11/12/2007
HEIDELBERG PHARMA AG starts second clinical phase II study with FOSALVUDINE
GlobeNewswire
2/5/2007
Recruitment completed for phase IIa trial with fosfluridine tidoxil in actinic keratosis
GlobeNewswire
10/9/2006
Start of clinical phase II with Fosalvudine for treatment of HIV-infected patients